On hepatotoxicity of drugs used in dermatology
- Authors: Denisova E.V1,2, Denieva M.I3,4, Dvoryankova E.V1, Plieva K.T5, Sobolev V.V1, Korsunskaya I.M1
-
Affiliations:
- Center for Theoretical Problems of Physicochemical Pharmacology Russian Academy of Sciences
- Moscow Research and Practical Center for Dermatovenereology and Cosmetology Moscow Healthcare Department
- Chechen State University
- Republican Dermatovenereology Dispensary
- Moscow Research and Practical Center for Dermatovenereology and Cosmetolog Moscow Healthcare Department
- Issue: Vol 31, No 9 (2020)
- Pages: 52-57
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114292
- DOI: https://doi.org/10.29296/25877305-2020-09-09
- ID: 114292
Cite item
Abstract
Full Text
About the authors
E. V Denisova
Center for Theoretical Problems of Physicochemical Pharmacology Russian Academy of Sciences; Moscow Research and Practical Center for Dermatovenereology and Cosmetology Moscow Healthcare Department
Email: marykor@bk.ru
Candidate of Medical Sciences Moscow; Moscow
M. I Denieva
Chechen State University; Republican Dermatovenereology Dispensary
Email: marykor@bk.ru
Candidate of Medical Sciences Groznyi; Groznyi
E. V Dvoryankova
Center for Theoretical Problems of Physicochemical Pharmacology Russian Academy of Sciences
Email: marykor@bk.ru
MD Moscow
K. T Plieva
Moscow Research and Practical Center for Dermatovenereology and Cosmetolog Moscow Healthcare Department
Email: marykor@bk.ru
Moscow
V. V Sobolev
Center for Theoretical Problems of Physicochemical Pharmacology Russian Academy of Sciences
Email: marykor@bk.ru
Candidate of Biological Sciences Moscow
I. M Korsunskaya
Center for Theoretical Problems of Physicochemical Pharmacology Russian Academy of Sciences
Email: marykor@bk.ru
Professor, MD Moscow
References
- Devarbhavi H., Raj S. Drug-induced liver injury with skin reactions: Drugs and host risk factors, clinical phenotypes and prognosis. Liver Int. 2019; 39 (5): 802-11. doi: 10.1111/liv.14004
- Andrade R.J., Chalasani N., Björnsson E.S. et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019; 5 (1): 58. doi: 10.1038/s41572-019-0105-0
- Liu L.U., Schiano T.D. Vitamin A (retinol). Hepatotoxicity of herbal medications, vitamins and natural hepatotoxins. In, Kaplowitz N., DeLeve L.D., eds. Drug-induced liver disease. 2nd ed. New York: Informa Healthcare USA, 2007; pp. 744-6.
- Grimaud J.C., Langier R., Costa-Legre M.C. et al. Hepatitis due to etretinate. Presse Med. 1985; 14: 844-5.
- Kreiss C., Amin S., Nalesnik M.A. et al. Severe cholestatic hepatitis in a patient taking acitretin. Am J Gastroenterol. 2002; 97: 775-7.
- Pang M.L., Murase J.E., Koo J. An updated review of acitretin-a systemic retinoid for the treatment of psoriasis. Expert Opin Drug Metab Toxicol. 2008; 4: 953-64. doi: 10.1517/17425255.4.7.953
- Chalasani N., Fontana R.J., Bonkovsky H.L. et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008; 135: 1924-34.
- Sauder M.B., Cheung L., Beecker J. Acitretin-induced hepatitis: when to monitor cholestatic enzymes. J Cutan Med Surg. 2015; 19: 115-20. doi: 10.2310/7750.2014.14051
- Kragballe K., Jansen C.T., Geiger J.M. et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Dermatol Venereol. 1989; 69: 35-40.
- Lérisson M., Ripault M.P., Pageaux G.P. et al. Hepatitis after retinoid percutaneous administration. Clin Res Hepatol Gastroenterol. 2014; 38: e99-e101.
- Pona A., Cardenasde la Garza J.A., Haidari W. et al. Abnormal liver function tests in acne patients receiving isotretinoin. J Dermatolog Treat. 2019; 1-4. doi: 10.1080/09546634.2019.1662882
- Colombo D., Cassano N., Altomare G. et al. Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study. Int J Immunopathol Pharmacol. 2010; 23 (4): 1143-52. doi: 10.1177/039463201002300418
- Khattri S., Shemer A., Rozenblit M. et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol. 2014; 133 (6): 1626-34. doi: 10.1016/j.jaci.2014.03.003
- Klintmalm G.B., Iwatsuki S., Starzl T.E. Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation. 1981; 32 (6): 488-9. doi: 10.1097/00007890-198112000-00007
- Kahan B.D., Flechner S.M., Lorber M.I. et al. Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation. 1987; 43 (2): 197-204. doi: 10.1097/00007890-198702000-00007
- Lorber M.I., Van Buren C.T., Flechner S.M. et al. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation. 1987; 43 (2):35-40. doi: 10.1097/00007890-198701000-00009
- Chalasani N., Bonkovsky H.L., Fontana R. et al. United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology. 2015; 148: 1340-52. e7. doi: 10.1053/j.gastro.2015.03.006
- Harper J.I., Ahmed I., Barclay G. et al. Cyclosporine for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000; 142 (1): 52-8. doi: 10.1046/j.1365-2133.2000.03241.x
- Walker D, Jacobe H. Phototherapy in the age of biologics. Semin Cutan Med Surg. 2011; 30: 190-8. doi: 10.1016/j.sder.2011.08.004
- Berg M., Ros A.M. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. Photodermatol Photoimmunol Photomed. 1994; 10: 217-20.
- Choi H.J., Kim S., Hann S.K. et al. The effect on liver transaminases of 5-methoxypsoralen used in systemic photochemotherapy. Ann Dermatol. 1995; 7: 51-3.
- McNeely W., Goa K.L. 5-methoxypsoralen: a review of its effects in psoriasis and vitiligo. Drugs. 1998; 56: 667-90. doi: 10.2165/00003495-199856040-00015
- Wenk K.S., Arrington K.C., Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011; 25: 383-91. doi: 10.1111/j.1468-3083.2010.03841.x
- Langman G., Hall P.M., Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol. 2001; 16: 1395-401. doi: 10.1046/j.1440-1746.2001.02644.x
- Haustein U.F., Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000; 14: 382-8. doi: 10.1046/j.1468-3083.2000.00058.x
- Ng L.C., Lee Y.Y., Lee C.K. et al. A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia. Int J Dermatol. 2013; 52: 102-5. doi: 10.1111/j.1365-4632.2011.05436.x
- Ros S., Juanola X., Condom E. et al. Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving longterm methotrexate therapy. Scand J Rheumatol. 2002; 31: 330-6. doi: 10.1080/030097402320817040
- Candelli M., Nista E.C., Pignataro G. et al. Steatohepatitis during methylprednisolone therapy for ulcerative colitis exacerbation. J Intern Med. 2003; 253: 391-2. doi: 10.1046/j.1365-2796.2003.01108.x
- Stravitz R.T., Sanyal A.J. Drug-induced steatohepatitis. Clin Liver Dis. 2003; 7: 435-51. doi: 10.1016/s1089-3261(03)00027-8
- Dourakis S.P., Sevastianos V.A., Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol. 2002; 97: 1074-5. doi: 10.1111/j.1572-0241.2002.05644.x
- Shiota G., Harada K., Oyama K. et al. Severe exacerbation of hepatitis after short-term corticosteroid therapy in a patients with «latent» chronic hepatitis B. Liver. 2000; 20: 415-20.
- Takahashi A., Kanno Y., Takahashi Y. et al. Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report. World J Gastroenterol. 2008; 14 (35): 5474-7. doi: 10.3748/wjg.14.5474
- Marino M., Morabito E., Brunetto M.R. et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid. 2004; 14: 403-6. doi: 10.1089/105072504774193276
- Мехтиев С.Н., Мехтиева О.А., Смирнова М.Н. Фиброз печени как показание для терапии у больных хроническими гепатитами. Эффективная фармакотерапия. 2015; 2: 22-33
- Василенко И.А., Долгова Г.В., Сорокоумова Г.М. и др. Сравнительное изучение гепатопротективных препаратов Эссенциале® форте Н, Фосфоглив, Эссливер форте. РМЖ. 2013; 21 (13): 681-4
- Недогода С.В., Чумачек Е.В., Санина М.С. и др. Препарат «Фосфоглив®» в терапии неалкогольной жировой болезни печени: предварительные результаты многоцентрового рандомизированного двойного слепого плацебоконтролируемого исследования «Гепард» (PHG-M2/P0212). Клинические перспективы гастроэнтерологии, гепатологии. 2015; 5: 16-22
- Денисова Е.В., Дворянкова Е.В., Плиева К.Т. и др. Патологии гепатобилиарной системы у больных псориазом. Эффективная фармакотерапия. 2018; 21: 18-23
- Денисова Е.В., Дворянкова Е.В., Дениева М.И. и др. Обоснование применения гепатопротекторов при псориазе. Врач. 2018; 29 (9): 85-8 https://doi.org/10.29296/25877305-2018-09-20
- Пирузян А.Л., Денисова Е.В., Дворянкова Е.В. и др. Влияние липидного профиля на коморбидные состояния при псориазе. Врач. 2019; 30 (10): 32-4 https://doi.org/10.29296/25877305-2019-10-06